Skip to main content
Abstracts PO66

High-Confidence Discordance Among Large Language Models in Acute Myeloid Leukemia Gray-Zone Decision-Making

Yan Leyfman, MD – NY Presbyterian Hospital; Noam Levi, BS – University of California, Irvine, CA, USA; Tuba Basit, MBBS – Dow Medical College, Dow University of Health Sciences,Karachi, Pakistan; Ayesha Junaid, MBBS – Dow Medical College, Dow University of Health Sciences, Karachi, Pakistan; Ayanth Theyver, N/A – West Ranch High School, LA, California; Havish Thatavarthi, N/A – West Ranch High School, LA, California; Shivani Shukla, MD – St. Luke's University Hospital Network, Bethlehem, Pennsylvania, USA; Vraj Rangrej, MBBS – Mayo Clinic Florida Jacksonville, Florida, US; Soumiya Nadar, MD – Tbilisi State Medical University Tbilisi, Georgia; Adeena Musheer, MBBS – Dow Medical College, Dow University of Health Sciences, Karachi, Pakistan; Zara Baloch, MBBS – Shaheed Zulqar Ali Bhutto Medical University, Islamabad, Pakistan; Helena Sanchez Coloma, Dental Student – Harvard University, Massachusetts, USA; Harshal Chorya, MBBS – Medical College Baroda, Baroda, India; Connor Yost, DO – Creighton University School of Medicine - Phoenix, USA; Muhammad Salman Faisal, MD – OU Health, University of Oklahoma, USA; Arturo Loaiza-Bonilla, MD – Co-founder and Chief Medical AI Officer at Massive Bio, Inc.; Yazan Migdady, MD, MSc – University of Michigan Health-West, Michigan, USA; Chandler Park, MD – Norton Cancer Institute,Louisville, KY, USA
Introduction/Background/Significance: Large language models (LLMs) are increasingly used for medical information retrieval, clinical reasoning, and decision support. However, most oncology benchmarks emphasize factual recall or guideline-based questions with clearly correct answers and provide limited insight into performance when treatment decisions depend on expert judgment. Acute myeloid leukemia (AML) is well suited to evaluating reasoning under uncertainty because contemporary management requires integration of molecular risk, measurable residual disease, transplant candidacy, prior hypomethylating agent/venetoclax exposure, germline predisposition, patient fitness, and evolving therapeutic options. We evaluated inter-model concordance, repeated-run reproducibility, and model-reported confidence across clinically ambiguous AML management scenarios.

Materials and Methods/Case Presentation/Objective: Twenty single-step, multiple-choice AML vignettes were evaluated by ChatGPT, Claude, Gemini, and OpenEvidence. Each model completed three independent runs per vignette, generating 240 responses. Repeated runs were aggregated using prespecified rules: three identical responses were classified as stable, while a two-of-three valid majority determined the final answer. The primary endpoint was inter-model agreement measured using Gwet's AC1. Secondary endpoints included Fleiss' κ, pairwise raw agreement, complete consensus, response-pattern distribution, within-model repeated-run reliability, and model-reported confidence. Wilson 95% confidence intervals were used for proportions. Agreement coefficients and confidence summaries were estimated using 10,000 whole-vignette clustered bootstrap resamples. A sensitivity analysis recalculated confidence using only runs contributing to the final aggregated answer.

Results/Description/Main Outcome Measure(s):

All 240 expected responses and confidence values were complete, and all 80 model-vignette combinations yielded valid final responses. Across the 20 vignettes, inter-model agreement was substantial by Gwet's AC1 (0.611; 95% bootstrap CI, 0.425-0.793) and moderate by Fleiss' κ (0.506; 95% bootstrap CI, 0.270-0.708). Mean pairwise agreement was 69.2%, ranging from 60.0% to 75.0%. Complete four-model consensus occurred in only 10 of 20 vignettes (50.0%; 95% CI, 29.9-70.1). Among the remaining vignettes, 6 had a 3-1 split, 1 had a 2-2 split, and 3 produced a 2-1-1 pattern. High-confidence disagreement was present in 6 of 10 discordant vignettes (60.0%; 95% CI, 31.3-83.2) and was unchanged in the confidence sensitivity analysis. Within-model reliability varied substantially, with Gwet's AC1 ranging from 0.679 to 1.000. Mean model-reported confidence also varied widely, from 69.6% to 93.7%.



Conclusion(s).: Across AML gray-zone scenarios, contemporary LLMs demonstrated only moderate-to-substantial concordance and reached complete consensus in half of cases. Most importantly, discordant recommendations frequently persisted despite high model-reported confidence, indicating that apparent certainty may not reliably identify when an LLM's recommendation requires additional scrutiny. These findings support disease-specific benchmarking that evaluates reproducibility, cross-model disagreement, and uncertainty recognition rather than factual accuracy alone. Because no physician reference standard was included, this study measures model concordance rather than clinical correctness; blinded leukemia-expert adjudication is required to determine whether disagreement reflects legitimate clinical equipoise or potentially unsafe reasoning.

Trademarked Items:

References: